CN104450747B - 用于治疗Leber遗传性视神经病变的重组腺相关病毒‑NADH脱氢酶亚单位4基因全长以及药剂 - Google Patents
用于治疗Leber遗传性视神经病变的重组腺相关病毒‑NADH脱氢酶亚单位4基因全长以及药剂 Download PDFInfo
- Publication number
- CN104450747B CN104450747B CN201410491726.XA CN201410491726A CN104450747B CN 104450747 B CN104450747 B CN 104450747B CN 201410491726 A CN201410491726 A CN 201410491726A CN 104450747 B CN104450747 B CN 104450747B
- Authority
- CN
- China
- Prior art keywords
- medicament
- cag
- aav2
- nadh dehydrogenase
- full length
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100021506 NADH-ubiquinone oxidoreductase chain 4 Human genes 0.000 title claims abstract description 83
- 108010035095 NADH dehydrogenase subunit 4 Proteins 0.000 title claims abstract description 71
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 35
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 title claims abstract description 24
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 title claims abstract description 20
- 241000702421 Dependoparvovirus Species 0.000 title abstract description 7
- 239000002773 nucleotide Substances 0.000 claims abstract description 7
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 7
- 241001300078 Vitrea Species 0.000 claims abstract description 5
- 230000031857 establishment of mitochondrion localization Effects 0.000 claims abstract description 4
- 101001109052 Homo sapiens NADH-ubiquinone oxidoreductase chain 4 Proteins 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 8
- 210000004907 gland Anatomy 0.000 claims description 7
- 239000013603 viral vector Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000012408 PCR amplification Methods 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 229940068977 polysorbate 20 Drugs 0.000 claims description 3
- -1 α, α-trehalose dihydrate compound Chemical class 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- CMXXUDSWGMGYLZ-XRIGFGBMSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride;hydrate Chemical compound O.Cl.OC(=O)[C@@H](N)CC1=CN=CN1 CMXXUDSWGMGYLZ-XRIGFGBMSA-N 0.000 claims 1
- 229960003882 histidine monohydrochloride monohydrate Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 14
- 210000003470 mitochondria Anatomy 0.000 abstract description 13
- 238000001890 transfection Methods 0.000 abstract description 10
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract description 2
- 230000014509 gene expression Effects 0.000 description 18
- 210000001525 retina Anatomy 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000010166 immunofluorescence Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000001328 optic nerve Anatomy 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 3
- 101150115542 Cox10 gene Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000004410 intraocular pressure Effects 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 101100440806 Cereibacter sphaeroides (strain ATCC 17023 / DSM 158 / JCM 6121 / CCUG 31486 / LMG 2827 / NBRC 12203 / NCIMB 8253 / ATH 2.4.1.) ctaB gene Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- 108020005196 Mitochondrial DNA Proteins 0.000 description 2
- 101100114478 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pft-1 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 102000057593 human F8 Human genes 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000003733 optic disk Anatomy 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 229940047431 recombinate Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 description 1
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010008795 Chromatopsia Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101150100316 ND4 gene Proteins 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 101150024923 da gene Proteins 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960003446 histidine monohydrochloride Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000001232 limbus corneae Anatomy 0.000 description 1
- 210000000627 locus coeruleus Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000004233 retinal vasculature Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410491726.XA CN104450747B (zh) | 2014-09-23 | 2014-09-23 | 用于治疗Leber遗传性视神经病变的重组腺相关病毒‑NADH脱氢酶亚单位4基因全长以及药剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410491726.XA CN104450747B (zh) | 2014-09-23 | 2014-09-23 | 用于治疗Leber遗传性视神经病变的重组腺相关病毒‑NADH脱氢酶亚单位4基因全长以及药剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104450747A CN104450747A (zh) | 2015-03-25 |
CN104450747B true CN104450747B (zh) | 2018-02-09 |
Family
ID=52897498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410491726.XA Active CN104450747B (zh) | 2014-09-23 | 2014-09-23 | 用于治疗Leber遗传性视神经病变的重组腺相关病毒‑NADH脱氢酶亚单位4基因全长以及药剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104450747B (zh) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102574849B1 (ko) * | 2016-11-04 | 2023-09-06 | 다케다 야쿠힌 고교 가부시키가이샤 | 아데노-연관 바이러스 제형 |
CN109970861B (zh) * | 2017-12-27 | 2021-06-11 | 武汉纽福斯生物科技有限公司 | 一种靶向线粒体的nd4融合蛋白及其制备方法和应用 |
WO2019241206A1 (en) * | 2018-06-11 | 2019-12-19 | Gensight Biologics Sa | Recombinant aav vectors and methods of using the same |
CN110846392A (zh) * | 2018-08-20 | 2020-02-28 | 武汉纽福斯生物科技有限公司 | 一种重组腺相关病毒或含其的试剂盒及其应用 |
WO2020010491A1 (zh) * | 2018-07-09 | 2020-01-16 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用 |
CN111068071A (zh) * | 2018-10-22 | 2020-04-28 | 武汉纽福斯生物科技有限公司 | 基因治疗Leber遗传学视神经病变 |
CN110724695A (zh) * | 2018-06-29 | 2020-01-24 | 武汉纽福斯生物科技有限公司 | 一种编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 |
CN113476484A (zh) * | 2018-06-29 | 2021-10-08 | 武汉纽福斯生物科技有限公司 | 治疗遗传性视神经病变的组合物和方法 |
WO2020000641A1 (zh) * | 2018-06-29 | 2020-01-02 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位蛋白的核酸及其应用 |
EP3814492A4 (en) | 2018-06-29 | 2022-02-23 | Wuhan Neurophth Biotechnology Limited Company | COMPOSITIONS AND METHODS OF TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY |
CN111073899B (zh) * | 2018-10-19 | 2021-01-01 | 武汉纽福斯生物科技有限公司 | 一种编码人nadh脱氢酶亚单位4蛋白的核酸及其应用 |
CN110656117A (zh) * | 2018-06-29 | 2020-01-07 | 武汉纽福斯生物科技有限公司 | 一种编码人nadh脱氢酶亚单位6蛋白的核酸及其应用 |
CN110699367B (zh) * | 2018-07-09 | 2021-06-11 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用 |
CA3109432A1 (en) | 2018-08-20 | 2020-02-27 | Wuhan Neurophth Biotechnology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
CN110857440B (zh) * | 2018-08-23 | 2021-02-19 | 武汉纽福斯生物科技有限公司 | 重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用 |
CN109207520B (zh) * | 2018-09-25 | 2022-05-10 | 北京锦篮基因科技有限公司 | Leber遗传性视神经病变的基因药物 |
CN110964748B (zh) * | 2018-09-29 | 2022-09-02 | 武汉纽福斯生物科技有限公司 | 含线粒体靶向序列的载体及其构建方法和应用 |
CN113025633A (zh) * | 2019-12-09 | 2021-06-25 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102634527A (zh) * | 2012-04-11 | 2012-08-15 | 华中科技大学同济医学院附属同济医院 | 重组人nadh脱氢酶亚单位4基因及其表达载体构建方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2014141056A (ru) * | 2012-03-12 | 2016-05-10 | МЕДИММЬЮН, ЭлЭлСи | Лечение рассеянного склероза при помощи антитела к cd19 |
-
2014
- 2014-09-23 CN CN201410491726.XA patent/CN104450747B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102634527A (zh) * | 2012-04-11 | 2012-08-15 | 华中科技大学同济医学院附属同济医院 | 重组人nadh脱氢酶亚单位4基因及其表达载体构建方法 |
Non-Patent Citations (1)
Title |
---|
GU299216.1;Paterson,R.G,et al;《GENBANK》;20100202;1 * |
Also Published As
Publication number | Publication date |
---|---|
CN104450747A (zh) | 2015-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104450747B (zh) | 用于治疗Leber遗传性视神经病变的重组腺相关病毒‑NADH脱氢酶亚单位4基因全长以及药剂 | |
CN102634527B (zh) | 重组人nadh脱氢酶亚单位4基因及其表达载体构建方法 | |
CN107184969A (zh) | 一种a型赛尼卡谷病毒灭活疫苗及其制备方法和应用 | |
CN104721817B (zh) | 一种疫苗组合物及其制备方法和应用 | |
CN104877971B (zh) | 一种可以缓解小鼠心衰症状的携带mg53基因的腺相关病毒载体 | |
CN104480142A (zh) | 一种鸭瘟病毒基因缺失转移载体及其应用 | |
CN104928260A (zh) | 一种牛传染性鼻气管炎病毒ibrv-jn03分离株及其应用 | |
CN103370077B (zh) | 猪繁殖与呼吸综合征病毒的商业化规模生产方法 | |
CN108421037A (zh) | 一种猪伪狂犬病/猪细小病毒病二联灭活疫苗及其悬浮培养制备方法 | |
CN108676092A (zh) | 一种防治新型鸭呼肠孤病毒的卵黄抗体及其制备方法 | |
CN108704128A (zh) | 一种犬瘟热细小病毒二联亚单位疫苗 | |
CN103060356A (zh) | 鸭瘟病毒缺失gE基因转移载体及其构建方法 | |
CN115141273B (zh) | 一种猫杯状病毒的单克隆抗体及其应用 | |
CN113278595B (zh) | 一种鸭腺病毒3型菌株、鸭腺病毒卵黄抗体及其制备方法和应用 | |
CN109550045A (zh) | 猪圆环病毒3型、猪细小病毒和猪流感三联灭活疫苗及其制备方法 | |
CN108498794A (zh) | 一种防治新型鸭呼肠孤病毒的灭活疫苗及其制备方法 | |
CN101444629B (zh) | 一种非注射用的基因治疗药物及其药盒 | |
CN114432332A (zh) | circUTRN在制备治疗心力衰竭药物中的应用、重组载体和治疗心力衰竭的药物 | |
CN106916832A (zh) | O型口蹄疫病毒重组核酸、重组疫苗株及其制备方法和应用 | |
CN107137705B (zh) | 猪伪狂犬gE基因缺失病毒灭活疫苗的生产方法 | |
CN101444628B (zh) | 一种治疗勃起功能障碍症的基因治疗药物及其药盒 | |
CN114517209B (zh) | 环状RNA circTTC3过表达腺相关病毒载体、腺相关病毒及其应用 | |
CN104651378B (zh) | 一种猪瘟疫苗感染性cDNA及其构建方法和应用 | |
CN116284350B (zh) | 一种猫疱疹病毒单克隆抗体及其制备方法和应用 | |
CN108379555A (zh) | Fgf21在制备治疗由血管紧张素ⅱ引发的高血压和/或血管病损伤的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180112 Address after: 430000, Hubei, East Lake Province, Wuhan hi tech Development Zone, 666 hi tech Avenue, Wuhan National Bio Industry Base Project B, C and D District R & D building B1, C270-C271 Applicant after: Wuhan Niufusi Biological Technology Co. Ltd. Address before: 430030 Department of Ophthalmology, Tongji Hospital, 1095 Jiefang Avenue, Hubei, Wuhan Applicant before: Li Bin |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20150325 Assignee: Newforce (Suzhou) Biotechnology Co.,Ltd. Assignor: Wuhan Niufusi Biological Technology Co.,Ltd. Contract record no.: X2021420000011 Denomination of invention: Recombinant adeno-associated virus NADH dehydrogenase subunit 4 gene for the treatment of Leber hereditary optic neuropathy Granted publication date: 20180209 License type: Common License Record date: 20210322 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Newforce (Suzhou) Biotechnology Co.,Ltd. Assignor: Wuhan Niufusi Biological Technology Co.,Ltd. Contract record no.: X2021420000011 Date of cancellation: 20210709 |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20150325 Assignee: Newforce (Suzhou) Biotechnology Co.,Ltd. Assignor: Wuhan Niufusi Biological Technology Co.,Ltd. Contract record no.: X2021420000020 Denomination of invention: Full length of recombinant adeno-associated virus NADH dehydrogenase subunit 4 gene and agent for the treatment of Leber hereditary optic neuropathy Granted publication date: 20180209 License type: Common License Record date: 20210726 |
|
EE01 | Entry into force of recordation of patent licensing contract |